Compare Eli Lilly And Co (LLY) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nasdaq100 ETF — how do they compare? Eli Lilly And Co trades at $1,160.92 (market cap $1.02T), while Nasdaq100 ETF trades at $705.66. The key difference: Eli Lilly And Co pays a 0.6% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals.
| LLY | QQQ | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $746.16 |
52-Week Low | $625.65 | $553.88 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
QQQ trades at $696.06, up 0.1% on the day, with technical indicators showing a bearish trend amid neutral oscillators. The ETF faces mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights concentration in big tech and institutional position adjustments, while a future dividend of $0.81 is scheduled for July 2026.
Outlook remains cautious due to technical bearishness and divided analyst views. Key risks include tech sector volatility and macroeconomic factors influencing rate decisions. Upside potential hinges on sustained AI-driven growth, but investors should weigh concentration risks in Nasdaq-100 holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
